QuidelOrtho Corporation (LON:0A55)
London · Delayed Price · Currency is GBP · Price in USD 43.50
-0.14 (-0.31%)
At close: Jan 31, 2025
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 29, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 2, 2022 | Jan '21 Jan 3, 2021 | 2015 - 2020 |
Labs | 1.43B | Log In | Log In | Log In | Log In | Upgrade |
Labs Growth | 3.83% | Log In | Log In | Log In | Log In | Upgrade |
Point of Care | 694.10M | Log In | Log In | Log In | Log In | Upgrade |
Point of Care Growth | -13.20% | Log In | Log In | Log In | Log In | Upgrade |
Molecular Diagnostics | 24.00M | Log In | Log In | Log In | Log In | Upgrade |
Molecular Diagnostics Growth | -0.39% | Log In | Log In | Log In | Log In | Upgrade |
Immunohematology | 522.60M | Log In | Log In | Log In | Log In | Upgrade |
Immunohematology Growth | 2.84% | Log In | Log In | Log In | Log In | Upgrade |
Donor Screening | 115.50M | Log In | Log In | Log In | Log In | Upgrade |
Donor Screening Growth | -45.54% | Log In | Log In | Log In | Log In | Upgrade |
EBITDA by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 29, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 2, 2022 | Jan '21 Jan 3, 2021 | 2015 - 2020 |
North America Adjusted EBITDA | 892.10M | Log In | Log In | Log In | Log In | Upgrade |
North America Adjusted EBITDA Growth | - | Log In | Log In | Log In | Log In | Upgrade |
EMEA Adjusted EBITDA | 46.50M | Log In | Log In | Log In | Log In | Upgrade |
EMEA Adjusted EBITDA Growth | - | Log In | Log In | Log In | Log In | Upgrade |
China Adjusted EBITDA | 130.50M | Log In | Log In | Log In | Log In | Upgrade |
China Adjusted EBITDA Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other Geographies Adjusted EBITDA | 133.50M | Log In | Log In | Log In | Log In | Upgrade |
Other Geographies Adjusted EBITDA Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Corporate Adjusted EBITDA | -659.70M | Log In | Log In | Log In | Log In | Upgrade |
Corporate Adjusted EBITDA Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 29, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 2, 2022 | Jan '21 Jan 3, 2021 | 2015 - 2020 |
North America | 1.62B | Log In | Log In | Log In | Log In | Upgrade |
North America Growth | -8.61% | Log In | Log In | Log In | Log In | Upgrade |
EMEA | 335.80M | Log In | Log In | Log In | Log In | Upgrade |
EMEA Growth | 4.47% | Log In | Log In | Log In | Log In | Upgrade |
China | 325.00M | Log In | Log In | Log In | Log In | Upgrade |
China Growth | 3.10% | Log In | Log In | Log In | Log In | Upgrade |
Other Geographies | 502.30M | Log In | Log In | Log In | Log In | Upgrade |
Other Geographies Growth | 5.88% | Log In | Log In | Log In | Log In | Upgrade |